Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MacroGenics, Inc. (MGNX : NSDQ)

• Company Description    MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. Number of Employees: 341

• Price / Volume Information    Yesterday's Closing Price: $1.46 Daily Weekly Monthly 20 Day Moving Average: 2,554,511 shares Shares Outstanding: 63.09 (millions) Market Capitalization: $92.11 (millions) Beta: 1.59 52 Week High: $5.77 52 Week Low: $0.99 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.98% -21.62% 12 Week 13.18% -3.33% Year To Date -55.08% -57.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9704 MEDICAL CENTER DRIVE - Rockville,MD 20850 USA ph: 301-251-5172 fax: 301-251-5321 info@macrogenics.com http://www.macrogenics.com

• General Corporate Information    Officers Scott Koenig - Chief Executive Officer;President and Director James Karrels - Senior Vice President;Chief Financial Officer and Beth Smith - Vice President; Controller and Treasurer Karen Ferrante - Director William Heiden - Director Peer Information MacroGenics, Inc. (BJCT) MacroGenics, Inc. (CADMQ) MacroGenics, Inc. (APNO) MacroGenics, Inc. (UPDC) MacroGenics, Inc. (IMTIQ) MacroGenics, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 556099109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 63.09 Most Recent Split Date: (:1) Beta: 1.59 Market Capitalization: $92.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.16 Price/Cash Flow: - Price / Sales: 0.60 EPS Growth vs. Year Ago Period: 22.62% vs. Previous Quarter: -160.00% Sales Growth vs. Year Ago Period: 44.90% vs. Previous Quarter: -31.83% ROE 06/30/25 - - 03/31/25 - -59.84 12/31/24 - -66.95 ROA 06/30/25 - - 03/31/25 - -23.45 12/31/24 - -27.46 Current Ratio 06/30/25 - - 03/31/25 - 3.28 12/31/24 - 3.92 Quick Ratio 06/30/25 - - 03/31/25 - 3.11 12/31/24 - 3.92 Operating Margin 06/30/25 - - 03/31/25 - -36.23 12/31/24 - -44.65 Net Margin 06/30/25 - - 03/31/25 - -36.23 12/31/24 - -44.65 Pre-Tax Margin 06/30/25 - - 03/31/25 - -35.62 12/31/24 - -44.03 Book Value 06/30/25 - - 03/31/25 - 1.25 12/31/24 - 1.85 Inventory Turnover 06/30/25 - - 03/31/25 - 4.52 12/31/24 - 8.77 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©